Literature DB >> 6287657

Action of cholecystokinin-octapeptide on sphincter of Oddi basal pressure and phasic wave activity in humans.

J Toouli, W J Hogan, J E Geenen, W J Dodds, R C Arndorfer.   

Abstract

The human sphincter of Oddi (SO) exhibits phasic wave activity over a 4 to 6 mm segment. Approximately 60% of these waves occur in an antegrade direction, 14% are retrograde, and 26% occur simultaneously. Because cholecystokinin-octapeptide (CCK-OP) stimulates the flow of bile into the duodenum, its effect on SO phasic wave contractions and contraction sequences was evaluated at ERCP manometry. An infused triple-lumen catheter of 1.7 mm outer diameter with side orifices spaced 2 mm apart was stationed in the SO segment so that all three orifices recorded phasic pressure waves. We studied 31 patients with normal ductal anatomy and normal SO pressures. In 21 of these patients CCK-OP (20 ng/kg) was given intravenously after a 2- to 3-minute baseline recording was obtained. Pressure recordings were continued for up to 10 minutes following CCK-OP administration. CCK-OP caused a significant inhibition in the frequency and amplitude of SO phasic waves as well as a significant decrease in basal SO pressure. Before CCK-OP most phasic contractions were antegrade, and after CCK-OP the sequence pattern remained unchanged. We conclude that CCK-OP reduces or transiently abolishes SO phasic contractions but that it does not change their temporal sequence. In addition, CCK-OP produces a decrease in basal SO pressure. These findings suggest that the action of CCK-OP in humans is to inhibit SO phasic activity and reduce SO basal pressure to allow increased flow of bile.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6287657

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  26 in total

Review 1.  Direct neuronal interactions between the duodenum and the sphincter of Oddi.

Authors:  A L Kennedy; G T Saccone; G M Mawe
Journal:  Curr Gastroenterol Rep       Date:  2000-04

2.  Role of duodenum on sphincter of Oddi motility in conscious dogs.

Authors:  Yukio Sonoda; Maosheng Dong; Hiroyuki Konomi; Masahiko Kawamoto; Kiichiro Kobayashi; Koji Yamaguchi; Masao Tanaka
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

3.  Is hepatobiliary scintigraphy insensitive for the diagnosis of sphincter of Oddi dysfunction?

Authors:  L Madácsy; A Szepes; V Bertalan; P Funch-Jensen
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

4.  Controlled study of the effect of nicardipine and ceruletide on the sphincter of Oddi.

Authors:  G M Fullarton; S Falconer; A Campbell; W R Murray
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

5.  Paradoxical response to cerulein on sphincter of Oddi in the patient with gastrectomy.

Authors:  K Odani; Y Nimura; A Yasui; Y Akita; S Shionoya
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

6.  Topical glyceryl trinitrate relaxes the sphincter of Oddi.

Authors:  W Luman; A Pryde; R C Heading; K R Palmer
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

7.  Manometric diagnosis of sphincter of Oddi spasm as a cause of postcholecystectomy pain and the treatment by endoscopic sphincterotomy.

Authors:  M Tanaka; S Ikeda; S Matsumoto; H Yoshimoto; F Nakayama
Journal:  Ann Surg       Date:  1985-12       Impact factor: 12.969

8.  Sphincter of Oddi manometry. Paradoxical response to secretin but not to CCK in alcoholic patients with no pancreatic disease.

Authors:  R Laugier; R Gerolami; C Renou
Journal:  Int J Pancreatol       Date:  1998-04

9.  Oddi sphincter function after canine auto-pancreas transplantation with bladder drainage.

Authors:  Gui-Chen Li; Chun-Hui Yuan; Ying Cheng; Yong-Feng Liu
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

10.  Intestinal dysmotility in patients with sphincter of Oddi dysfunction. A reason for failed response to sphincterotomy.

Authors:  E E Soffer; F C Johlin
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.